ArticleFrontiers in endocrinology2025
The global incidence rate of type 2 diabetes related chronic kidney disease and predictions by Bayesian age-period-cohort analysis: findings from the Global Burden of Disease Study 2019.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Determinants of hypoglycemia and hospitalization among hemodialysis patients with type 2 diabetes: insights from a multicenter study in a resource-limited healthcare system.Renal failure · 2026Article
- Burden of chronic kidney disease due to type 2 diabetes mellitus in Asia: A retrospective analysis.Medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: To evaluate the spatial-temporal changes in the incidence of type 2 diabetes related chronic kidney disease (CKD-T2DM) from 1990 to 2019, categorized by age and sex in 21 regions with different socio-demographic indexes (SDI), and to predict the incidence rate between 2020 and 2030. Methods: Data on the burden of CKD-T2DM were obtained from the Global Burden of Disease Study 2019. Age-standardized incidence rates (ASIR) were estimated by sex, age, region, SDI, and specifically in China. The trends of ASIR were assessed using Joinpoint model to calculate the average annual percentage changes (AAPCs) and their 95% confidence intervals. Prediction was conducted using the Bayesian age-period-cohort (BAPC) model. Result: In 2019, the ASIR of global CKD-T2DM increased with age in both sexes, and was highest in the older 75 age group. The ASIR of CKD-T2DM in males was higher than those in females. Overall, the global ASIR of CKD-T2DM increased from 1990 to 2019 in both sexes and all age groups. The most significant increase was observed in the 15-49 age group [males: AAPC=1.42, 95%CI:(1.35-1.49); females: AAPC=1.18,95%CI:(1.13-1.23)]. Besides, the upward trends in ASIR of CKD-T2DM were observed in most SDI regions and GBD regions. The changing trends in ASIR of CKD-T2DM in China were similar to the global trends. Finally, the predicted ASIR was also found to be increased globally and also in China in both sex from 2020 to 2030. Conclusion: The global CKD-T2DM incidence rates increased from 1990 to 2019 in both sexes, most regions and in China., and also increased globally between 2020 and 2030. Therefore, it is important to input more medical resources and establish prevention strategies for the increasing trends of CKD-T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.